Core Viewpoint - The announcement emphasizes the integrity and accuracy of the financial report for the third quarter of 2025, ensuring that there are no false records or misleading statements [2][10]. Financial Data - The financial statements for the third quarter of 2025 have not been audited [3][7]. - The report includes major accounting data and financial indicators, although specific figures are not provided in the text [3][4]. Shareholder Information - The report mentions the total number of ordinary shareholders and the situation of the top ten shareholders, but specific details are not disclosed [5]. Meeting and Approval - The third meeting of the supervisory board was held on October 28, 2025, with all three supervisors present, and the meeting complied with relevant laws and regulations [9][10]. - The supervisory board unanimously approved the third quarter report, confirming that the preparation and review processes adhered to legal and internal regulations [10].

赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）第三届监事会第七 次会议通知于 2025 年 10 月 23 日以书面送达等方式通知各位监事。会议于 2025 年 10 月 29 日在北京市海淀区高梁桥斜街 59号中坤大厦 7层公司会议室以现场和通讯相结合的方式召开。 本次会议应出席监事 3人，实际出席监事 3人。本次会议由监事会主席于长春先生召集并主持。 本次会议的召开符合《中华人民共和国公司法》等有关法律、法规、规范性文件及《公司章程》 《监事会议事规则》等的规定，会议召开程序合法有效。 经与会监事认真讨论，审议并通过如下事项： 1、审议通过"关于赛诺医疗科学技术股份有限公司 2025 年第三季度报告的议案" 经与会监事审议，一致通过"关于赛诺医疗科学技术股份有限公司 2025 年第三季度报告 的议案"，同意《赛诺医疗科学技术股份有限公司 2025 年第三季度报告》。 监事会认为：《赛诺医疗科学技术股份有限公司 2025 年第三季度报告》的编制和审议程 序符合相关法律、法规及《公司章程》等内部规章制度的规定；《赛诺医疗科学技术股份有限 公司 2025 年第三季度报告》的内容与格式符合相关规定 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2025-051 赛诺医疗科学技术股份有限公司 关于第三届监事会第七次会议决议的公告 经与会监事审议，一致通过"关于赛诺医疗科学技术股份有限公司 2025 年第三 季度报告的议案"，同意《赛诺医疗科学技术股份有限公司 2025 年第三季度报告》。 监事会认为：《赛诺医疗科学技术股份有限公司 2025 年第三季度报告》的编制 和审议程序符合相关法律、法规及《公司章程》等内部规章制度的规定；《赛诺医 疗科学技术股份有限公司 2025 年第三季度报告》的内容与格式符合相关规定，公允 地反映了公司 2025 年前三季度的财务状况和经营成果等事项；《赛诺医疗科学技术 股份有限公司 2025 年第三季度报告》编制过程中，未发现公司参与第三季度报告编 制和审议的人员有违反保密规定的行为；监事会全体成员保证《赛诺医疗科学技术 股份有限公司 2025 年第三季度报告》披露的信息真实、准确、完整，不存在任何虚 假记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性依法承担 法律责任。 公司《2025 年第三季度报告》的具体内容，详见公司于同日在中国证监会指定 信息披 ...

Group 1 - The core viewpoint of the article highlights Sino Medical's financial performance in Q3 2023, showing a revenue increase and a positive net profit [1] - Sino Medical reported approximately 364 million yuan in revenue for the first three quarters of 2025, representing a year-on-year increase of 14.24% [1] - The net profit attributable to shareholders of the listed company was approximately 21.12 million yuan, with a basic earnings per share of 0.05 yuan [1] Group 2 - As of the report, Sino Medical's market capitalization stands at 8.5 billion yuan [2]

Financial Performance - The company's operating revenue for Q3 2025 reached ¥123,378,511.92, representing a year-on-year increase of 17.73%[3]. - The total profit for the period was ¥10,506,327.09, with a year-to-date total profit of ¥33,516,889.46, reflecting a significant increase of 300.41% compared to the previous year[3][8]. - Net profit attributable to shareholders for Q3 was ¥7,276,401.53, marking a year-on-year growth of 150.51%[3][8]. - Total operating revenue for the first three quarters of 2025 reached ¥363,854,525.58, an increase of 14.3% compared to ¥318,486,443.24 in the same period of 2024[17]. - Net profit for the first three quarters of 2025 was ¥20,719,725.46, a significant recovery from a net loss of ¥14,931,400.83 in the same period of 2024[18]. - The total comprehensive income for the first three quarters of 2025 was ¥20,953,883.99, a recovery from a loss of ¥16,488,648.07 in the same period of 2024[18]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥83,974,895.27, an increase of 68.89% compared to the previous year[3][8]. - Cash inflow from operating activities for the first three quarters of 2025 is 413,401,906.35 CNY, an increase of 8.3% from 379,785,264.54 CNY in the same period of 2024[19]. - Cash outflow for investing activities is 31,015,450.99 CNY, down 66.0% from 91,099,183.91 CNY in the previous year[20]. - Net cash flow from investing activities is -30,981,098.74 CNY, an improvement from -72,000,968.51 CNY in the same period last year[20]. - Cash inflow from financing activities totals 73,934,400.00 CNY, a decrease of 39.3% from 121,906,687.94 CNY in the previous year[20]. - Net cash flow from financing activities is 13,663,827.42 CNY, down 77.0% from 59,422,575.01 CNY year-over-year[20]. - The ending balance of cash and cash equivalents is 357,698,265.28 CNY, compared to 224,939,661.92 CNY at the end of the previous year, reflecting a 59.0% increase[20]. Assets and Liabilities - Total assets increased by 2.94% from the previous year-end, reaching ¥1,338,809,666.31[4]. - Total liabilities increased slightly to ¥406,995,292.36 from ¥402,216,111.69, showing a growth of 1.9%[15]. - Total equity attributable to shareholders rose to ¥900,750,469.58 from ¥866,885,685.69, marking an increase of 3.9%[15]. - Accounts receivable increased to RMB 13,633,071.77 from RMB 7,473,696.25, representing an increase of approximately 82.5%[12]. - Inventory stood at RMB 102,766,470.80, up from RMB 89,505,811.67, indicating an increase of about 14.7%[13]. - Short-term borrowings increased to RMB 91,472,917.17 from RMB 53,049,209.71, marking an increase of approximately 72.2%[13]. Research and Development - Research and development expenses totaled ¥51,600,668.69 for the quarter, a decrease of 13.60% year-on-year, and accounted for 41.82% of operating revenue[3]. - Research and development expenses were ¥92,757,264.16, down from ¥106,407,498.18, indicating a 13% reduction[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 29,360[10]. - Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd. holds 71,859,417 shares, accounting for 17.27% of the total shares[10]. - The company has not reported any significant changes in the shareholding structure or any related party transactions among the top shareholders[11]. - The company has not received any declarations regarding other shareholders having related party relationships or concerted action agreements[11]. Other Information - The company plans to continue focusing on market expansion and new product development to drive future growth[3]. - The company has not adopted new accounting standards or interpretations for the year 2025[21]. - The report is unaudited and prepared by Sino Medical Science Technology Co., Ltd[19].

Group 1 - The core point of the article highlights that Sino Medical (688108) experienced a significant decline in stock price, closing at 20.51 yuan, down 18.58% on October 29, with a trading volume of 1.585 billion yuan and a turnover rate of 18.62% [2] - The stock was listed on the daily trading alert due to a price drop exceeding 15% [2] - The top five trading departments accounted for a total transaction of 459 million yuan, with net selling amounting to 51.23 million yuan [2] Group 2 - The main buying department was CITIC Securities' Beijing Anwai Street branch, with a purchase amount of 82.34 million yuan, followed by Guotai Junan Securities' headquarters with 43.21 million yuan [3] - The leading selling department was CITIC Securities (Shandong) with a selling amount of 81.63 million yuan [3] - The stock saw a net outflow of 193 million yuan in main funds on the same day [3] Group 3 - Over the past six months, the stock has been on the trading alert list eight times, with an average price increase of 9.28% the day after being listed and an average increase of 31.38% in the following five days [3]

Market Performance - The Sci-Tech Innovation Board (STAR Market) index rose by 1.18%, closing at 1489.12 points, with a total trading volume of 4.52 billion shares and a turnover of 232.84 billion yuan [1] - Among the tradable stocks on the STAR Market, 296 stocks closed higher, with 10 stocks increasing by over 10% and 25 stocks rising between 5% and 10% [1] Trading Activity - The average turnover rate for the STAR Market was 2.37%, with 3 stocks having a turnover rate exceeding 20% and 14 stocks between 10% and 20% [1] - The highest turnover rate was recorded by C Yicai at 51.17%, with a closing price increase of 3.88% and a daily trading volume of 2.216 billion yuan [1] - C Heyuan, another new stock, saw a significant increase of 24.28% with a turnover rate of 50.96% and a trading volume of 2.171 billion yuan [1] Sector Analysis - In the high turnover stocks, the electronics sector had the most representation, with 32 stocks, followed by power equipment and computer sectors with 15 and 10 stocks, respectively [2] - Among the high turnover stocks, 49 stocks experienced net inflows of main funds, with Huahong Company, Aters, and Goodway receiving the highest net inflows of 449 million yuan, 418 million yuan, and 116 million yuan, respectively [2] Leverage and Financial Performance - A total of 64 stocks in the high turnover category received net purchases of leveraged funds, with notable increases in financing balances for Ju Chen Co., Huafeng Technology, and Western Superconducting, which saw increases of 462 million yuan, 343 million yuan, and 313 million yuan, respectively [3] - Among the high turnover stocks, 52 companies reported their Q3 earnings, with Zhongyou Technology, Shijia Photon, and Huafeng Technology showing significant net profit growth rates of 1074.35%, 727.74%, and 558.51%, respectively [3]

Core Viewpoint - The medical device sector experienced a decline of 0.42% on October 29, with Sainuo Medical leading the drop, while the overall market indices showed positive performance [1]. Group 1: Market Performance - On October 29, the Shanghai Composite Index closed at 4016.33, up by 0.7% [1]. - The Shenzhen Component Index closed at 13691.38, up by 1.95% [1]. Group 2: Capital Flow - The medical device sector saw a net outflow of 522 million yuan from main funds, while retail investors contributed a net inflow of 193 million yuan [2]. - Speculative funds recorded a net inflow of 329 million yuan into the medical device sector [2].

Market Overview - The A-share market experienced a strong rally on October 29, with the Shanghai Composite Index surpassing 4000 points, reaching a 10-year high. The ChiNext Index rose nearly 3%, and the North Exchange 50 Index surged over 8% [1][2]. Shanghai Composite Index - The Shanghai Composite Index closed at 4016.33 points, up 0.7%. The Shenzhen Component Index increased by 1.95% to 13691.38 points, while the ChiNext Index rose by 2.93% to 3324.27 points. The North Exchange 50 Index saw a significant increase of 8.41% [2][4]. Trading Volume - The total trading volume across the Shanghai, Shenzhen, and North exchanges reached 22909 billion yuan, an increase of approximately 1250 billion yuan compared to the previous day [2]. Sector Performance Photovoltaic Industry - The photovoltaic sector saw explosive growth, with stocks like Sungrow Power Supply rising over 15%, reaching a historical high. Other companies such as Longi Green Energy, Tongwei Co., and JA Solar Technology also hit their daily limit [2][9]. - The market capitalization of Sungrow Power Supply is now nearly 400 billion yuan [9]. Nonferrous Metals Sector - The nonferrous metals sector performed strongly, with companies like China Tungsten High-Tech and Jiangxi Copper nearing their daily limit. The sector was driven by rising prices in tungsten and aluminum [13][15]. - Tungsten prices have increased due to growing demand and supply constraints, with black tungsten concentrate prices rising to 288,000 yuan per ton [15]. Securities Sector - The securities sector also saw gains, with companies like Huashan Securities and Northeast Securities reaching their daily limit during intraday trading [2]. Hainan Free Trade Zone - Stocks related to the Hainan Free Trade Zone, such as Hainan Development and Hainan Airlines, also experienced significant gains, hitting their daily limit [2]. Regulatory Developments - The China Securities Regulatory Commission (CSRC) announced plans to improve the listing mechanism for the North Exchange, aiming to enhance the quality of listed companies and stimulate market activity [7]. Future Outlook - Analysts suggest that the recent adjustments in the North Exchange have created new valuation opportunities, particularly for newly listed companies with strong profit potential and innovative attributes [7]. Conclusion - The A-share market's strong performance on October 29 reflects a shift in investor focus towards sectors like photovoltaic and nonferrous metals, driven by regulatory support and improving market conditions [1][2][7].

半导体产业链掀涨价潮。 业绩暴增股继续大幅上涨。今天（10月29日）早盘，储能龙头阳光电源一度升破180元/股大关，续创历史新高。消息面上，10月28日晚间，阳光电源发布 了2025年三季度财报，前三季度实现总营收为664亿元，同比增长33%；净利润为119亿元，同比增长56%。 科技股持续火爆，玻璃纤维、光伏逆变器、量子技术、储能、覆铜板等相关题材均涨超1%。整体来看，在AI产业持续向好的大背景下，半导体产业链掀 起涨价潮，存储芯片、先进封装等均有涨价消息，近期电子特气也传出大幅涨价消息。 大利空，688108，3分钟"20cm"跌停 赛诺医疗(688108)今天早盘大幅低开，截至9点33分左右即封死"20cm"跌停。10点37分左右，该股被大单撬开跌停板，随后有所反弹。截至上午收盘，该 股报21.13元/股，下跌16.12%，市值87.9亿元。 消息面上，赛诺医疗 10月28日晚间公告称，公司控股子公司赛诺神畅医疗科技有限公司的COMETIU自膨式颅内药物涂层支架系统注册申请未获得国家药 品监督管理局批准，国家药监局已对相关注册申请结果予以公示。 价格暴涨70%~90% 近期涨价题材表现凶猛。比如有色金属 ...